<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Case ReportInternational Journal of Advances in Medicine

Publication:
Rifampicin induced acute thrombocytopenia with skin rashes: a case report

Int J Adv Med. 2023;10(11):790-792.DOI10.18203/2349-3933.ijam20233210

Thumbnail Image
View on the journal's website(opens in a new tab)

Abstract

Rifampicin is an essential component of the treatment regimen for tuberculosis. Extensive clinical experience has shown that the drug has mild adverse effect, but on rare occasions, it can cause life threatening adverse reactions like thrombocytopenia. Blajchman et al first described rifampicin-induced thrombocytopenia in 1970. Since then, almost 40 cases have been documented in the literature and a recent review by Cooper and Ghanima included rifampicin in the group of not uncommon drugs that cause immune-mediated thrombocytopenia. Diagnosis of drug-induced immune thrombocytopenia is by identifying clinical symptoms and a careful evaluation of the suspected causative drug. The physician treating tuberculosis patients must be aware of this rare life-threatening complication, when we detected early, is completely reversible.

Keywords

Affiliations

  1. Department of Respiratory Medicine, Indira Gandhi Medical College and Research Institute, Puducherry, India

Full item record